Biotech Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO(TM) as the Brand Name for MAT9001 January 4, 2021
Biotech AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections January 4, 2021
Biotech EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics January 3, 2021
Biotech ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Fortress Biotech, Inc. Investors of Important January 26 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – FBIO January 2, 2021
Biotech MERGER INVESTIGATION ALERT: Halper Sadeh LLP Encourages NK, PRGX, CBLI, and IPHI Shareholders to Contact the Firm January 2, 2021
Biotech FBIO LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Fortress Biotech, Inc. Investors with Losses over $100K to Seek Counsel Before Important January 26 Deadline in Securities Class Action – FBIO December 31, 2020